###begin article-title 0
###xml 43 58 43 58 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15&#8211;KLK3&#8211;KLK2</italic>
A comprehensive resequence analysis of the KLK15-KLK3-KLK2 locus on chromosome 19q13.33
###end article-title 0
###begin p 1
###xml 46 50 46 50 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 306 310 306 310 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 772 776 772 776 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 1023 1024 1023 1024 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1024 1025 1024 1025 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1119 1120 1119 1120 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1120 1121 1120 1121 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1333 1337 1333 1337 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 1395 1400 1395 1400 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 1405 1409 1405 1409 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 1516 1520 1516 1520 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
Single nucleotide polymorphisms (SNPs) in the KLK3 gene on chromosome 19q13.33 are associated with serum prostate-specific antigen (PSA) levels. Recent genome wide association studies of prostate cancer have yielded conflicting results for association of the same SNPs with prostate cancer risk. Since the KLK3 gene encodes the PSA protein that forms the basis for a widely used screening test for prostate cancer, it is critical to fully characterize genetic variation in this region and assess its relationship with the risk of prostate cancer. We have conducted a next-generation sequence analysis in 78 individuals of European ancestry to characterize common (minor allele frequency, MAF >1%) genetic variation in a 56 kb region on chromosome 19q13.33 centered on the KLK3 gene (chr19:56,019,829-56,076,043 bps). We identified 555 polymorphic loci in the process including 116 novel SNPs and 182 novel insertion/deletion polymorphisms (indels). Based on tagging analysis, 144 loci are necessary to tag the region at an r2 threshold of 0.8 and MAF of 1% or higher, while 86 loci are required to tag the region at an r2 threshold of 0.8 and MAF >5%. Our sequence data augments coverage by 35 and 78% as compared to variants in dbSNP and HapMap, respectively. We observed six non-synonymous amino acid or frame shift changes in the KLK3 gene and three changes in each of the neighboring genes, KLK15 and KLK2. Our study has generated a detailed map of common genetic variation in the genomic region surrounding the KLK3 gene, which should be useful for fine-mapping the association signal as well as determining the contribution of this locus to prostate cancer risk and/or regulation of PSA expression.
###end p 1
###begin title 2
Electronic supplementary material
###end title 2
###begin p 3
The online version of this article (doi:10.1007/s00439-009-0751-5) contains supplementary material, which is available to authorized users.
###end p 3
###begin title 4
Introduction
###end title 4
###begin p 5
###xml 99 103 99 103 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 378 382 378 382 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR23">2006</xref>
###xml 568 572 568 572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR22">2003</xref>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR32">2004</xref>
###xml 819 823 819 823 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2009</xref>
###xml 841 845 841 845 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2009</xref>
###xml 71 74 <span type="species:ncbi:9606">men</span>
Prostate cancer is the most commonly diagnosed non-cutaneous cancer in men in the US (Jemal et al. 2008). A widely used test for prostate cancer screening is based on measuring prostate-specific antigen (PSA) protein levels in serum. However, elevated PSA levels can also be caused by nonmalignant conditions such as benign prostatic hyperplasia and prostatitis (Punglia et al. 2006). Although the PSA test has led to the diagnosis of earlier stage prostate cancers, the specificity and sensitivity of the test is not optimal for clinical applications (Punglia et al. 2003; Thompson et al. 2004). Consequently, large randomized screening trials are currently ongoing to assess the benefits of the PSA test for prostate cancer screening and mortality rates. Although interim results have been published (Andriole et al. 2009; Schroder et al. 2009) the benefits, if any, of the PSA test as a diagnostic screening tool for prostate cancer are still not clear.
###end p 5
###begin p 6
###xml 221 226 221 226 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2008b</xref>
###xml 302 306 302 306 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 707 711 707 711 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2008</xref>
###xml 981 985 981 985 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2008</xref>
###xml 1267 1272 1267 1272 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR10">2008a</xref>
###xml 1340 1345 1340 1345 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2008b</xref>
###xml 1568 1572 1568 1572 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR15">2009</xref>
###xml 1584 1588 1584 1588 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR33">2008</xref>
A recent genome wide association study (GWAS) of prostate cancer reported that several single nucleotide polymorphisms (SNPs) on chromosome 19q13.33 were associated with an increased risk of prostate cancer (Eeles et al. 2008b). The most significant SNP, rs2735839, is located 600 bp downstream of the KLK3 gene, which encodes kallikrein 3 (hK3), also known as PSA. A notable feature of this study was that control individuals were selected to have low PSA levels (<0.5 ng/ml). In a separate GWAS of prostate cancer conducted within the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial, the findings on chromosome 19 were not confirmed for prostate cancer susceptibility (Thomas et al. 2008). Further analysis of the results from the PLCO study indicated an association between rs2735839 and PSA levels; interestingly, when the controls were restricted to those with very low PSA levels, a strong association was observed with prostate cancer risk (Ahn et al. 2008). In the first study that reported the chromosome 19 association with prostate cancer, the authors reported evidence for association of rs2735839 and prostate cancer in additional studies unselected for PSA levels but the level of significance was substantially less (Eeles et al. 2008a) than in the discovery set with the low PSA controls (Eeles et al. 2008b). Additional studies have also shown association between rs2735839 and PSA levels in control individuals and with less aggressive prostate cancer, but selection biases for elevated PSA may have played a role (Kader et al. 2009; Xu et al. 2008). Thus, there is evidence that the locus on chromosome 19q13.33 is associated with PSA levels and possibly also prostate cancer.
###end p 6
###begin p 7
###xml 432 436 432 436 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 503 507 503 507 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 553 558 553 558 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 577 581 577 581 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 723 727 723 727 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 903 908 903 908 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 930 934 930 934 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
To conduct follow-up studies in this region of chromosome 19q33.13, we generated a map of common SNPs and insertion/deletion polymorphisms (indels) through a deep sequencing analysis of a 56 kb region flanking rs2735839 (chr19:56,019,829-56,076,043 bps; NCBI Build 36.3) in 78 unrelated individuals of European ancestry using a novel solution-based sequence capture method, combined with the Roche-454 platform (Rothberg and Leamon 2008). This region chosen for targeted resequencing is centered on the KLK3 gene but also includes the neighboring genes KLK15 (centromeric) and KLK2 (telomeric). We identified 555 polymorphic loci including 116 novel SNPs and 182 novel indels. Eleven coding variants were identified in the KLK3 gene, including five that result in non-synonymous amino acid changes and one that causes a frameshift in the protein. Four coding variants were identified in the neighboring KLK15 gene and five in the KLK2 gene. This catalog of common genetic variation establishes a foundation for comprehensively tagging the region in individuals of European ancestry for fine-mapping studies.
###end p 7
###begin title 8
Materials and methods
###end title 8
###begin title 9
Samples
###end title 9
###begin p 10
###xml 215 219 215 219 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2000</xref>
###xml 366 370 366 370 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR31">2008</xref>
###xml 386 390 386 390 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR34">2007</xref>
###xml 511 512 511 512 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 569 570 569 570 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 703 704 703 704 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 782 783 782 783 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
DNA samples were from 41 prostate cancer cases and 33 controls individuals (total 74) from the National Cancer Institute's (NCI) Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial (Gohagan et al. 2000). They were drawn from samples analyzed in the initial scan of the Cancer Genetics Markers of Susceptibility (CGEMS) Initiative () (Thomas et al. 2008; Yeager et al. 2007). Approximately half of the samples from prostate cancer cases were selected on the basis of high PSA levels (>4 ng/ml, n = 21) and the other half with low PSA levels (<4 ng/ml, n = 20). In a similar manner, approximately half of the control samples came from individuals with low normal PSA levels (<0.5 ng/ml, n = 17) while the other half were within the high normal range (2.5-3.9 ng/ml, n = 16).
###end p 10
###begin p 11
DNA samples from 18 individuals in HapMap CEU pedigrees were sequenced: 2 three generation CEPH families (14 individuals from families #1350 and #1444) and two sets of parents (4 individuals from families #1334 and #1340). Finally, two trios from YRI pedigrees were included (6 individuals from families #5 and #16).
###end p 11
###begin title 12
Region sequenced
###end title 12
###begin p 13
###xml 234 238 234 238 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 424 428 424 428 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2008</xref>
###xml 443 448 443 448 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2008b</xref>
###xml 686 691 686 691 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 693 697 693 697 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
We sequenced a 56 kb genomic region on chromosome 19 (56,019,829-56,076,043 bps, NCBI Build 36.3) selected based on the pattern of linkage disequilibrium (LD) around rs2735839 in the HapMap CEU samples using Haploview (Barrett et al. 2005). The region was selected to include the most significant SNP associated with prostate cancer and PSA levels, rs2735839, and the neighboring region based on the genetic map (Ahn et al. 2008; Eeles et al. 2008b). The boundaries were extended to include adjacent blocks based on the pattern of LD observed in this region using Phases I and II HapMap Caucasian samples (). Finally, we extended the region to fully include the three kallikrein genes: KLK15, KLK3 and KLK2.
###end p 13
###begin title 14
Primers, sequence capture and sequencing
###end title 14
###begin p 15
###xml 271 275 271 275 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR25">2000</xref>
Thirteen sets of long-range PCR primers were designed to cover the 56 kb region targeted. Amplicon size ranged from 3,442 to 5,099 bps and primer sets overlapped, on average, 377 bps with the adjacent amplicon. Primers were designed using Primer3 () (Rozen and Skaletsky 2000) and then quality checked in silico for uniqueness, potential sequence paralogy and DNA repeat sequences using the BLAT feature of the UCSC Genome Browser (). Next, NetPrimer () was used to check for secondary structures and PCR efficiencies. Primers were ordered from Integrated DNA Technologies (Coralville, IA). All primers and coordinates are supplied in Supplemental Table 1.
###end p 15
###begin p 16
###xml 158 162 158 162 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR2">2007</xref>
Biotinylated solution capture probe pools targeting the regions of interest were generated for sequence capture (Roche NimbleGen, Madison, WI) (Albert et al. 2007). Capture was performed in solution in 0.2 ml PCR strip tubes on a thermal cycler. After ~72 h, the capture probe/sample duplexes were bound to streptavidin magnetic beads. Captured samples were then amplified directly off the beads and prepped for sequencing (454 linker ligation). After long-range PCR, all sequencing protocols were followed in accordance with standard kits for the 454 GS FLX system ().
###end p 16
###begin title 17
Alignment and detection of polymorphisms
###end title 17
###begin p 18
###xml 714 715 714 715 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 809 810 809 810 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
We developed an automated computational pipeline to process sequence reads generated by 454 FLX Genome Sequencers. Whenever applicable, sequence reads from the same sample were pooled based on barcodes provided by Roche/454. Quality check (QC) was performed using vendor-supplied software and sequence reads that passed QC were aligned to the target genomic region (chr19:56,019,829-56,076,043 bps) using the MOSAIK software (). The resulting assembly was analyzed using a column by column approach and potential polymorphic sites and most likely genotypes were called based on a set of heuristic rules. The minimal sequence coverage depth was set to 20 reads for each nucleotide position. In addition, the ratio (r) of forward and reverse reads was determined. To avoid directional bias, an optimal range of r was set between 10 and 90%. Homozygous genotype calls were made when the most frequent allele was present in at least 85% of the reads. Heterozygous genotype calls were made when the two most frequent alleles were represented in 30-70% of reads. Genotype calls were not made if the above criteria were not met. Manual inspections aided by the NextGENe software () and Consed () were performed to quality assurance (QA) and to resolve ambiguous cases.
###end p 18
###begin p 19
Supplemental Table 2 includes flanking sequences for polymorphic loci that passed QC and had over 50% completion rates.
###end p 19
###begin title 20
Concordance analysis
###end title 20
###begin p 21
Concordance analysis between the re-sequencing data and CGEMS PLCO scan data was assessed for 74 individuals (cases and controls). Genotype data for the region (chr19:56,019,829-56,076,043 bps) was downloaded from HapMap () and the 1000 Genomes Project (; imputed genotypes were not included; Data release: May, 2009) to evaluate genotype concordance between re-sequencing data and HapMap or 1000 Genomes Project data, respectively. Twenty-one HapMap samples were used to calculate concordance between the present study and HapMap data. Ten HapMap samples were used to calculate concordance between the present study and the 1000 Genomes Project data. 102 HapMap samples, included in the 1000 Genomes Project data set were used to calculate concordance between HapMap and 1000 Genomes Project data. Genotype concordance was computed using the GLU software package ().
###end p 21
###begin p 22
###xml 15 16 13 14 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 53 57 51 55 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR20">1998</xref>
###xml 287 288 285 286 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q</italic>
###xml 367 371 365 369 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2003</xref>
###xml 480 484 478 482 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR30">2003</xref>
A two group chi2 test of equal proportions (Newcombe 1998) was performed to evaluate the differences in minor allele frequencies (MAFs) for each of 243 SNPs detected both in this study and the CEU population available in the 1000 Genomes Project data. To correct for multiple testing, a q value was calculated using the QVALUE software package (Storey and Tibshirani 2003) for each test. This method measures significance in terms of a false discovery rate (Storey and Tibshirani 2003). Statistical analyses were performed using the R statistical software ().
###end p 22
###begin title 23
Descriptive statistics
###end title 23
###begin p 24
###xml 306 310 306 310 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
###xml 511 515 511 515 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR4">2005</xref>
Genotype completion, MAF estimations, deviations from fitness for Hardy-Weinberg proportion (HWP), pairwise linkage disequilibrium (LD) and tag SNP selection were computed using the GLU software package. Inheritance check analysis was performed on samples from HapMap families in Haploview (Barrett et al. 2005). Data from 78 unrelated individuals of European ancestry (66 cases/controls and 12 HapMap CEU) was used for SNP tagging using the GLU software package. LD was visualized in Haploview (Barrett et al. 2005).
###end p 24
###begin title 25
In silico genomic analysis
###end title 25
###begin p 26
###xml 245 253 <span type="species:ncbi:9606">Children</span>
The presence of highly conserved regions, copy number variation and predicted regulatory elements was assessed by using publicly available databases and bioinformatics tools: the UCSC genome browser (), the Copy Number Variation database at the Children's Hospital of Philadelphia (), the Database of Genomic Variants () and the VISTA Enhancer database ().
###end p 26
###begin title 27
Results
###end title 27
###begin title 28
Sequence coverage and depth
###end title 28
###begin p 29
###xml 114 115 114 115 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig1" ref-type="fig">1</xref>
###xml 327 333 327 333 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;1</label>
###xml 421 436 421 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">horizontal line</italic>
###xml 545 566 545 566 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue horizontal lines</italic>
###xml 333 592 333 592 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="30">Coverage and sequence depth over the 56&#160;kb region sequenced on chromosome 19q13.33. The <italic>horizontal line</italic> at 70-fold represents the average depth and the line at 20-fold represents the cutoff for low coverage. The <italic>blue horizontal lines</italic> represent primer amplicon</p>
###xml 333 592 333 592 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="30">Coverage and sequence depth over the 56&#160;kb region sequenced on chromosome 19q13.33. The <italic>horizontal line</italic> at 70-fold represents the average depth and the line at 20-fold represents the cutoff for low coverage. The <italic>blue horizontal lines</italic> represent primer amplicon</p></caption>
###xml 592 592 592 592 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="439_2009_751_Fig1_HTML" id="MO1"/>
###xml 327 592 327 592 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig1"><label>Fig.&#160;1</label><caption><p textid="30">Coverage and sequence depth over the 56&#160;kb region sequenced on chromosome 19q13.33. The <italic>horizontal line</italic> at 70-fold represents the average depth and the line at 20-fold represents the cutoff for low coverage. The <italic>blue horizontal lines</italic> represent primer amplicon</p></caption><graphic position="anchor" xlink:href="439_2009_751_Fig1_HTML" id="MO1"/></fig>
The average depth and coverage in the genomic region sequenced (chr19:56,019,829-56,076,043 bps) is shown in Fig. 1. No gaps were observed in the coverage and the average depth was 70-fold (range 1- to 136-fold). Low coverage (<20-fold) was seen in six small regions (cumulative length 1,393 bp) listed in Supplemental Table 3.Fig. 1Coverage and sequence depth over the 56 kb region sequenced on chromosome 19q13.33. The horizontal line at 70-fold represents the average depth and the line at 20-fold represents the cutoff for low coverage. The blue horizontal lines represent primer amplicon
###end p 29
###begin p 30
###xml 88 103 88 103 <italic xmlns:xlink="http://www.w3.org/1999/xlink">horizontal line</italic>
###xml 212 233 212 233 <italic xmlns:xlink="http://www.w3.org/1999/xlink">blue horizontal lines</italic>
Coverage and sequence depth over the 56 kb region sequenced on chromosome 19q13.33. The horizontal line at 70-fold represents the average depth and the line at 20-fold represents the cutoff for low coverage. The blue horizontal lines represent primer amplicon
###end p 30
###begin title 31
Polymorphism discovery and quality control assessment
###end title 31
###begin p 32
###xml 165 169 165 169 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2000</xref>
###xml 707 708 707 708 <italic xmlns:xlink="http://www.w3.org/1999/xlink">P</italic>
###xml 718 719 718 719 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 754 755 754 755 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 90 98 <span type="species:ncbi:9606">patients</span>
Genotypes were called for 652 possible SNPs and indels in 74 samples from prostate cancer patients and controls from the PLCO Cancer Screening Trial (Gohagan et al. 2000), 18 HapMap CEU samples and 6 HapMap YRI samples. During data quality control assessment, samples were excluded when genotype completion was less than 50% or genotypes showed discordance with CGEMS PLCO or HapMap genotype data. After excluding four samples with 75% or less genotype concordance with the CGEMS PLCO data, concordance for the remaining samples was 100%. No samples were excluded based on low concordance with HapMap data (overall concordance 99.8%). Loci were excluded based on departures from Hardy-Weinberg equilibrium (P < 0.001, n = 1) or if they were monomorphic (n = 92) in our samples (Supplemental Table 4). No loci were dropped due to low completion rates. For inheritance check analysis, only members of the HapMap families were analyzed. No samples or SNPs were excluded on the basis of Mendelian errors (overall Mendelian error rate 0%).
###end p 32
###begin p 33
###xml 466 467 466 467 <italic xmlns:xlink="http://www.w3.org/1999/xlink">q</italic>
A comparison of our dataset with an early build of the 1000 Genomes Project data showed 95.6% concordance rate, which is not surprising based on the preliminary nature of the data release. The concordance between HapMap data and 1000 Genomes data was 97.1%. We did not observe significant differences in MAFs for 243 SNPs detected both in this study and the CEU population available in the 1000 Genomes Project data set (average difference in MAFs = 0.008, range of q values 0.22-1; median 1). The total number of SNPs present in the 1000 Genomes Project in the targeted region was 365 as compared to 373 in the present study.
###end p 33
###begin p 34
###xml 169 170 169 170 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab1" ref-type="table">1</xref>
###xml 1058 1065 1058 1065 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;1</label>
###xml 1065 1164 1065 1164 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="35">Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestry</p>
###xml 1065 1164 1065 1164 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="35">Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestry</p></caption>
###xml 1164 1172 1164 1172 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Category</th>
###xml 1172 1176 1172 1176 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">SNPs</th>
###xml 1176 1182 1176 1182 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="3">Indels</th>
###xml 1182 1196 1182 1196 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Total variants</th>
###xml 1196 1211 1196 1211 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Completion&#160;&gt;50%</th>
###xml 1164 1211 1164 1211 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="2">Category</th><th align="left" colspan="3">SNPs</th><th align="left" colspan="3">Indels</th><th align="left" rowspan="2">Total variants</th><th align="left" rowspan="2">Completion&#160;&gt;50%</th></tr>
###xml 1211 1220 1211 1218 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF&#160;&#8805;1%</th>
###xml 1220 1229 1218 1225 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF&#160;&#8805;5%</th>
###xml 1229 1232 1225 1228 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All</th>
###xml 1232 1241 1228 1235 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF&#160;&#8805;1%</th>
###xml 1241 1250 1235 1242 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF&#160;&#8805;5%</th>
###xml 1250 1253 1242 1245 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All</th>
###xml 1211 1253 1211 1245 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th></tr>
###xml 1164 1253 1164 1245 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="2">Category</th><th align="left" colspan="3">SNPs</th><th align="left" colspan="3">Indels</th><th align="left" rowspan="2">Total variants</th><th align="left" rowspan="2">Completion&#160;&gt;50%</th></tr><tr><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th></tr></thead>
###xml 1253 1258 1245 1250 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">dbSNP</td>
###xml 1258 1261 1250 1253 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">248</td>
###xml 1261 1264 1253 1256 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">211</td>
###xml 1264 1267 1256 1259 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">251</td>
###xml 1267 1268 1259 1260 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1268 1269 1260 1261 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">3</td>
###xml 1269 1270 1261 1262 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">6</td>
###xml 1270 1273 1262 1265 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">257</td>
###xml 1273 1276 1265 1268 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">236</td>
###xml 1253 1276 1245 1268 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">dbSNP</td><td char="." align="char">248</td><td char="." align="char">211</td><td char="." align="char">251</td><td char="." align="char">6</td><td char="." align="char">3</td><td char="." align="char">6</td><td char="." align="char">257</td><td char="." align="char">236</td></tr>
###xml 1282 1283 1274 1275 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1276 1283 1268 1275 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HapMap<sup>a</sup></td>
###xml 1283 1285 1275 1277 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">80</td>
###xml 1285 1287 1277 1279 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">68</td>
###xml 1287 1289 1279 1281 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">81</td>
###xml 1289 1290 1281 1282 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1290 1291 1282 1283 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1291 1292 1283 1284 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1292 1294 1284 1286 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">81</td>
###xml 1294 1296 1286 1288 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">80</td>
###xml 1276 1296 1268 1288 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HapMap<sup>a</sup></td><td char="." align="char">80</td><td char="." align="char">68</td><td char="." align="char">81</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">81</td><td char="." align="char">80</td></tr>
###xml 1304 1305 1296 1297 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1296 1305 1288 1297 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Illumina<sup>b</sup></td>
###xml 1305 1307 1297 1299 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">28</td>
###xml 1307 1309 1299 1301 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">26</td>
###xml 1309 1311 1301 1303 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29</td>
###xml 1311 1312 1303 1304 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1312 1313 1304 1305 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1313 1314 1305 1306 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1314 1316 1306 1308 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">29</td>
###xml 1316 1318 1308 1310 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27</td>
###xml 1296 1318 1288 1310 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Illumina<sup>b</sup></td><td char="." align="char">28</td><td char="." align="char">26</td><td char="." align="char">29</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">29</td><td char="." align="char">27</td></tr>
###xml 1318 1323 1310 1315 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Novel</td>
###xml 1323 1325 1315 1317 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">55</td>
###xml 1325 1327 1317 1319 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19</td>
###xml 1327 1330 1319 1322 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">116</td>
###xml 1330 1333 1322 1325 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">159</td>
###xml 1333 1335 1325 1327 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">66</td>
###xml 1335 1338 1327 1330 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">182</td>
###xml 1338 1341 1330 1333 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">298</td>
###xml 1341 1344 1333 1336 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">208</td>
###xml 1318 1344 1310 1336 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Novel</td><td char="." align="char">55</td><td char="." align="char">19</td><td char="." align="char">116</td><td char="." align="char">159</td><td char="." align="char">66</td><td char="." align="char">182</td><td char="." align="char">298</td><td char="." align="char">208</td></tr>
###xml 1344 1347 1336 1339 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All</td>
###xml 1347 1350 1339 1342 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">223</td>
###xml 1350 1353 1342 1345 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">162</td>
###xml 1353 1356 1345 1348 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">367</td>
###xml 1356 1359 1348 1351 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">165</td>
###xml 1359 1361 1351 1353 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">69</td>
###xml 1361 1364 1353 1356 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">188</td>
###xml 1364 1367 1356 1359 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">555</td>
###xml 1367 1370 1359 1362 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">444</td>
###xml 1344 1370 1336 1362 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">All</td><td char="." align="char">223</td><td char="." align="char">162</td><td char="." align="char">367</td><td char="." align="char">165</td><td char="." align="char">69</td><td char="." align="char">188</td><td char="." align="char">555</td><td char="." align="char">444</td></tr>
###xml 1253 1370 1245 1362 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">dbSNP</td><td char="." align="char">248</td><td char="." align="char">211</td><td char="." align="char">251</td><td char="." align="char">6</td><td char="." align="char">3</td><td char="." align="char">6</td><td char="." align="char">257</td><td char="." align="char">236</td></tr><tr><td align="left">HapMap<sup>a</sup></td><td char="." align="char">80</td><td char="." align="char">68</td><td char="." align="char">81</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">81</td><td char="." align="char">80</td></tr><tr><td align="left">Illumina<sup>b</sup></td><td char="." align="char">28</td><td char="." align="char">26</td><td char="." align="char">29</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">29</td><td char="." align="char">27</td></tr><tr><td align="left">Novel</td><td char="." align="char">55</td><td char="." align="char">19</td><td char="." align="char">116</td><td char="." align="char">159</td><td char="." align="char">66</td><td char="." align="char">182</td><td char="." align="char">298</td><td char="." align="char">208</td></tr><tr><td align="left">All</td><td char="." align="char">223</td><td char="." align="char">162</td><td char="." align="char">367</td><td char="." align="char">165</td><td char="." align="char">69</td><td char="." align="char">188</td><td char="." align="char">555</td><td char="." align="char">444</td></tr></tbody>
###xml 1164 1370 1164 1362 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Category</th><th align="left" colspan="3">SNPs</th><th align="left" colspan="3">Indels</th><th align="left" rowspan="2">Total variants</th><th align="left" rowspan="2">Completion&#160;&gt;50%</th></tr><tr><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th></tr></thead><tbody><tr><td align="left">dbSNP</td><td char="." align="char">248</td><td char="." align="char">211</td><td char="." align="char">251</td><td char="." align="char">6</td><td char="." align="char">3</td><td char="." align="char">6</td><td char="." align="char">257</td><td char="." align="char">236</td></tr><tr><td align="left">HapMap<sup>a</sup></td><td char="." align="char">80</td><td char="." align="char">68</td><td char="." align="char">81</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">81</td><td char="." align="char">80</td></tr><tr><td align="left">Illumina<sup>b</sup></td><td char="." align="char">28</td><td char="." align="char">26</td><td char="." align="char">29</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">29</td><td char="." align="char">27</td></tr><tr><td align="left">Novel</td><td char="." align="char">55</td><td char="." align="char">19</td><td char="." align="char">116</td><td char="." align="char">159</td><td char="." align="char">66</td><td char="." align="char">182</td><td char="." align="char">298</td><td char="." align="char">208</td></tr><tr><td align="left">All</td><td char="." align="char">223</td><td char="." align="char">162</td><td char="." align="char">367</td><td char="." align="char">165</td><td char="." align="char">69</td><td char="." align="char">188</td><td char="." align="char">555</td><td char="." align="char">444</td></tr></tbody></table>
###xml 1370 1374 1362 1366 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 1408 1414 1400 1406 <italic xmlns:xlink="http://www.w3.org/1999/xlink">indels</italic>
###xml 1453 1456 1445 1448 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAF</italic>
###xml 1370 1479 1362 1471 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="36"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>indels</italic> insertion and deletion polymorphisms, <italic>MAF</italic> minor allele frequency</p>
###xml 1479 1480 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1479 1506 1471 1498 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="37"><sup>a</sup>HapMap phase I, II and III</p>
###xml 1506 1507 1498 1499 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1506 1593 1498 1585 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="38"><sup>b</sup>Illumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs</p>
###xml 1370 1593 1362 1585 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="36"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>indels</italic> insertion and deletion polymorphisms, <italic>MAF</italic> minor allele frequency</p><p textid="37"><sup>a</sup>HapMap phase I, II and III</p><p textid="38"><sup>b</sup>Illumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs</p></table-wrap-foot>
###xml 1058 1593 1058 1585 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab1"><label>Table&#160;1</label><caption><p textid="35">Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="2">Category</th><th align="left" colspan="3">SNPs</th><th align="left" colspan="3">Indels</th><th align="left" rowspan="2">Total variants</th><th align="left" rowspan="2">Completion&#160;&gt;50%</th></tr><tr><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th><th align="left">MAF&#160;&#8805;1%</th><th align="left">MAF&#160;&#8805;5%</th><th align="left">All</th></tr></thead><tbody><tr><td align="left">dbSNP</td><td char="." align="char">248</td><td char="." align="char">211</td><td char="." align="char">251</td><td char="." align="char">6</td><td char="." align="char">3</td><td char="." align="char">6</td><td char="." align="char">257</td><td char="." align="char">236</td></tr><tr><td align="left">HapMap<sup>a</sup></td><td char="." align="char">80</td><td char="." align="char">68</td><td char="." align="char">81</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">81</td><td char="." align="char">80</td></tr><tr><td align="left">Illumina<sup>b</sup></td><td char="." align="char">28</td><td char="." align="char">26</td><td char="." align="char">29</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">0</td><td char="." align="char">29</td><td char="." align="char">27</td></tr><tr><td align="left">Novel</td><td char="." align="char">55</td><td char="." align="char">19</td><td char="." align="char">116</td><td char="." align="char">159</td><td char="." align="char">66</td><td char="." align="char">182</td><td char="." align="char">298</td><td char="." align="char">208</td></tr><tr><td align="left">All</td><td char="." align="char">223</td><td char="." align="char">162</td><td char="." align="char">367</td><td char="." align="char">165</td><td char="." align="char">69</td><td char="." align="char">188</td><td char="." align="char">555</td><td char="." align="char">444</td></tr></tbody></table><table-wrap-foot><p textid="36"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>indels</italic> insertion and deletion polymorphisms, <italic>MAF</italic> minor allele frequency</p><p textid="37"><sup>a</sup>HapMap phase I, II and III</p><p textid="38"><sup>b</sup>Illumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs</p></table-wrap-foot></table-wrap>
The final dataset for individuals of European ancestry contained genotypes from 78 individuals (66 PLCO and 12 unrelated HapMap samples) and 555 polymorphic loci (Table 1). These include 116 new SNPs, 182 new indels and 257 loci previously described in NCBI's dbSNP database (). The latter number includes 81 HapMap SNPs (). The average locus call (completion) rate was 74.4% (range 2.6-100%, median 87.2%) as shown in Supplemental Fig. 1. MAF estimates were computed for each locus and were on average 13.2% (range 0.6-50%, median 6.8%). The number of new SNPs and indels with MAF >5% was 85. Supplemental Fig. 2 shows the distribution of MAFs for new and known polymorphisms detected in the study. Since our indel calling algorithm is still being refined, these low-frequency variants should be treated as preliminary data and require validation. Hence, for the subsequent analysis we only included loci with completion rates >50% which included 444 polymorphic loci (112 new SNPs, 96 new indels and 236 loci previously described in NCBI's dbSNP database).Table 1Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestryCategorySNPsIndelsTotal variantsCompletion >50%MAF >/=1%MAF >/=5%AllMAF >/=1%MAF >/=5%AlldbSNP248211251636257236HapMapa8068810008180Illuminab2826290002927Novel551911615966182298208All22316236716569188555444SNPs single nucleotide polymorphisms, indels insertion and deletion polymorphisms, MAF minor allele frequencyaHapMap phase I, II and IIIbIllumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs
###end p 34
###begin p 35
Distribution of new and known SNPs and indels that were polymorphic in samples of European ancestry
###end p 35
###begin p 36
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 38 44 38 44 <italic xmlns:xlink="http://www.w3.org/1999/xlink">indels</italic>
###xml 83 86 83 86 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAF</italic>
SNPs single nucleotide polymorphisms, indels insertion and deletion polymorphisms, MAF minor allele frequency
###end p 36
###begin p 37
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aHapMap phase I, II and III
###end p 37
###begin p 38
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bIllumina HumanHap610 assay. Note that HapMap and Illumina SNPs are also part of dbSNPs
###end p 38
###begin title 39
###xml 16 27 16 27 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15, KLK3</italic>
###xml 32 36 32 36 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
Loci within the KLK15, KLK3 and KLK2 genes
###end title 39
###begin p 40
###xml 48 52 48 52 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 249 253 249 253 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 485 489 485 489 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 519 523 519 523 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1996</xref>
###xml 525 529 525 529 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1997</xref>
###xml 545 549 545 549 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1996</xref>
###xml 650 654 650 654 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 771 775 771 775 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR5">1996</xref>
###xml 777 781 777 781 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR6">1997</xref>
###xml 797 801 797 801 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2003</xref>
###xml 817 821 817 821 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR27">1996</xref>
Twenty polymorphic sites were identified in the KLK3 gene: five synonymous, five non-synonymous, one frameshift (resulting in a stop codon 23 amino acids downstream of the site) and nine variants that affect the 3' untranslated (3'UTR) of different KLK3 isoforms. The proximal promoter contains three androgen-responsive elements (AREs), ARE I, ARE II and ARE III, centered at -170 bp, -394 bp and -4,200 bp, respectively from the transcription start site, that are known to influence KLK3 expression (Cleutjens et al. 1996; 1997; Schuur et al. 1996). The presence of two SNPs known to overlap with functionally validated regulatory elements for the KLK3 gene was confirmed (rs266882 in ARE I and rs925013 in an upstream enhancer that contains ARE III) (Cleutjens et al. 1996; 1997; Cramer et al. 2003; Schuur et al. 1996).
###end p 40
###begin p 41
###xml 84 89 84 89 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 270 274 270 274 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
Four coding variants (three non-synonymous and one synonymous) were observed in the KLK15 gene. Three additional polymorphic sites were located in the 3' UTR region of the gene. Five coding variants (1 non-synonymous, 2 synonymous and 2 frameshift) were observed in the KLK2 gene and eight sites were located within the 3' UTR region. Supplemental Table 5 lists polymorphic loci observed in the three genes and the resulting changes in amino acid sequences of different KLK isoforms.
###end p 41
###begin title 42
Linkage disequilibrium (LD) and tag SNP selection
###end title 42
###begin p 43
###xml 319 320 319 320 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Fig2" ref-type="fig">2</xref>
###xml 641 647 641 647 <label xmlns:xlink="http://www.w3.org/1999/xlink">Fig.&#160;2</label>
###xml 739 740 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 740 741 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 845 850 845 850 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 852 856 852 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 858 862 858 862 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 647 935 647 935 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="44">Linkage disequilibrium (LD) plot across the KLK locus on chromosome 19q13.33 as measured by <italic>r</italic><sup>2</sup>. Polymorphisms in this study with MAF&#160;&gt;5% and completion rates &gt;50% are included. Relative location of <italic>KLK15</italic>, <italic>KLK3</italic>, <italic>KLK2</italic> and rs2735839 are shown. Coordinates are based on NCBI genome build 36.3</p>
###xml 647 935 647 935 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="44">Linkage disequilibrium (LD) plot across the KLK locus on chromosome 19q13.33 as measured by <italic>r</italic><sup>2</sup>. Polymorphisms in this study with MAF&#160;&gt;5% and completion rates &gt;50% are included. Relative location of <italic>KLK15</italic>, <italic>KLK3</italic>, <italic>KLK2</italic> and rs2735839 are shown. Coordinates are based on NCBI genome build 36.3</p></caption>
###xml 935 935 935 935 <graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="anchor" xlink:href="439_2009_751_Fig2_HTML" id="MO2"/>
###xml 641 935 641 935 <fig xmlns:xlink="http://www.w3.org/1999/xlink" id="Fig2"><label>Fig.&#160;2</label><caption><p textid="44">Linkage disequilibrium (LD) plot across the KLK locus on chromosome 19q13.33 as measured by <italic>r</italic><sup>2</sup>. Polymorphisms in this study with MAF&#160;&gt;5% and completion rates &gt;50% are included. Relative location of <italic>KLK15</italic>, <italic>KLK3</italic>, <italic>KLK2</italic> and rs2735839 are shown. Coordinates are based on NCBI genome build 36.3</p></caption><graphic position="anchor" xlink:href="439_2009_751_Fig2_HTML" id="MO2"/></fig>
Based on our sequence data, the map of LD of common variants (MAF >5%) demonstrates that there are two blocks of high LD in the telomeric part of the region from approximately 56,063-56,070 and 56,072-56,075 kb. On the other hand, the centromeric part of the region sequenced from ~56,020 to 56,063 kb has low LD (Fig. 2). The genetic map of this region has been refined compared to HapMap data (Supplemental Fig. 3); overall, the current sequence data corroborates the two HapMap recombination hotspots located at approximately 56,024-56,026 kb (recombination rate 54 cM/Mb) and 56,067-56,071 kb (recombination rate 31 cM/Mb), respectively.Fig. 2Linkage disequilibrium (LD) plot across the KLK locus on chromosome 19q13.33 as measured by r2. Polymorphisms in this study with MAF >5% and completion rates >50% are included. Relative location of KLK15, KLK3, KLK2 and rs2735839 are shown. Coordinates are based on NCBI genome build 36.3
###end p 43
###begin p 44
###xml 92 93 92 93 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 93 94 93 94 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 198 203 198 203 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 205 209 205 209 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 211 215 211 215 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
Linkage disequilibrium (LD) plot across the KLK locus on chromosome 19q13.33 as measured by r2. Polymorphisms in this study with MAF >5% and completion rates >50% are included. Relative location of KLK15, KLK3, KLK2 and rs2735839 are shown. Coordinates are based on NCBI genome build 36.3
###end p 44
###begin p 45
###xml 64 69 64 69 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2008b</xref>
###xml 108 112 108 112 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2008</xref>
###xml 238 239 238 239 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 239 240 239 240 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 404 405 404 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 638 639 638 639 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab2" ref-type="table">2</xref>
###xml 741 742 739 740 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 742 743 740 741 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 787 788 783 784 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 788 789 784 785 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 834 835 828 829 <xref xmlns:xlink="http://www.w3.org/1999/xlink" rid="Tab3" ref-type="table">3</xref>
###xml 836 843 830 837 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;2</label>
###xml 843 913 837 907 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="46">Tag SNP information, bins and coverage in samples of European ancestry</p>
###xml 843 913 837 907 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="46">Tag SNP information, bins and coverage in samples of European ancestry</p></caption>
###xml 913 921 907 915 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3">Category</th>
###xml 921 922 915 916 <italic xmlns:xlink="http://www.w3.org/1999/xlink">n</italic>
###xml 922 923 916 917 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 921 923 915 917 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="3"><italic>n</italic><sup>a</sup></th>
###xml 937 938 929 930 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 938 939 930 931 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 923 947 917 937 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">MAF&#160;&#8805;1% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th>
###xml 961 962 949 950 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 962 963 950 951 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 947 971 937 957 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="5">MAF&#160;&#8805;5% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th>
###xml 913 971 907 957 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" rowspan="3">Category</th><th align="left" rowspan="3"><italic>n</italic><sup>a</sup></th><th align="left" colspan="5">MAF&#160;&#8805;1% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th><th align="left" colspan="5">MAF&#160;&#8805;5% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th></tr>
###xml 971 985 957 971 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Bins monitored</th>
###xml 985 1003 971 989 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Variants monitored</th>
###xml 1003 1015 989 1001 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Coverage (%)</th>
###xml 1015 1029 1001 1015 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Bins monitored</th>
###xml 1029 1047 1015 1033 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" colspan="2">Variants monitored</th>
###xml 1047 1059 1033 1045 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left" rowspan="2">Coverage (%)</th>
###xml 971 1059 957 1045 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th></tr>
###xml 1059 1062 1045 1048 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</th>
###xml 1062 1064 1048 1050 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</th>
###xml 1064 1067 1050 1053 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</th>
###xml 1067 1069 1053 1055 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</th>
###xml 1069 1072 1055 1058 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</th>
###xml 1072 1074 1058 1060 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</th>
###xml 1074 1077 1060 1063 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Yes</th>
###xml 1077 1079 1063 1065 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">No</th>
###xml 1059 1079 1045 1065 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr>
###xml 913 1079 907 1065 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left" rowspan="3">Category</th><th align="left" rowspan="3"><italic>n</italic><sup>a</sup></th><th align="left" colspan="5">MAF&#160;&#8805;1% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th><th align="left" colspan="5">MAF&#160;&#8805;5% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th></tr><tr><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead>
###xml 1079 1084 1065 1070 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">dbSNP</td>
###xml 1084 1087 1070 1073 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">236</td>
###xml 1087 1089 1073 1075 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">96</td>
###xml 1089 1091 1075 1077 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">48</td>
###xml 1091 1094 1077 1080 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">233</td>
###xml 1094 1097 1080 1083 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">124</td>
###xml 1097 1099 1083 1085 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">65</td>
###xml 1099 1101 1085 1087 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">76</td>
###xml 1101 1103 1087 1089 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">10</td>
###xml 1103 1106 1089 1092 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">194</td>
###xml 1106 1108 1092 1094 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 1108 1110 1094 1096 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">85</td>
###xml 1079 1110 1065 1096 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">dbSNP</td><td char="." align="char">236</td><td char="." align="char">96</td><td char="." align="char">48</td><td char="." align="char">233</td><td char="." align="char">124</td><td char="." align="char">65</td><td char="." align="char">76</td><td char="." align="char">10</td><td char="." align="char">194</td><td char="." align="char">33</td><td char="." align="char">85</td></tr>
###xml 1116 1117 1102 1103 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1110 1117 1096 1103 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">HapMap<sup>b</sup></td>
###xml 1117 1119 1103 1105 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">80</td>
###xml 1119 1121 1105 1107 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">42</td>
###xml 1121 1124 1107 1110 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">102</td>
###xml 1124 1126 1110 1112 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">79</td>
###xml 1126 1129 1112 1115 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">278</td>
###xml 1129 1131 1115 1117 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">22</td>
###xml 1131 1133 1117 1119 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 1133 1135 1119 1121 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">53</td>
###xml 1135 1137 1121 1123 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67</td>
###xml 1137 1140 1123 1126 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">160</td>
###xml 1140 1142 1126 1128 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">30</td>
###xml 1110 1142 1096 1128 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">HapMap<sup>b</sup></td><td char="." align="char">80</td><td char="." align="char">42</td><td char="." align="char">102</td><td char="." align="char">79</td><td char="." align="char">278</td><td char="." align="char">22</td><td char="." align="char">33</td><td char="." align="char">53</td><td char="." align="char">67</td><td char="." align="char">160</td><td char="." align="char">30</td></tr>
###xml 1150 1151 1136 1137 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1142 1151 1128 1137 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Illumina<sup>c</sup></td>
###xml 1151 1153 1137 1139 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27</td>
###xml 1153 1155 1139 1141 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">21</td>
###xml 1155 1158 1141 1144 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">123</td>
###xml 1158 1160 1144 1146 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">27</td>
###xml 1160 1163 1146 1149 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">330</td>
###xml 1163 1164 1149 1150 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">8</td>
###xml 1164 1166 1150 1152 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">19</td>
###xml 1166 1168 1152 1154 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">67</td>
###xml 1168 1170 1154 1156 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">25</td>
###xml 1170 1173 1156 1159 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">202</td>
###xml 1173 1175 1159 1161 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">11</td>
###xml 1142 1175 1128 1161 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Illumina<sup>c</sup></td><td char="." align="char">27</td><td char="." align="char">21</td><td char="." align="char">123</td><td char="." align="char">27</td><td char="." align="char">330</td><td char="." align="char">8</td><td char="." align="char">19</td><td char="." align="char">67</td><td char="." align="char">25</td><td char="." align="char">202</td><td char="." align="char">11</td></tr>
###xml 1175 1180 1161 1166 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Novel</td>
###xml 1180 1183 1166 1169 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">208</td>
###xml 1183 1185 1169 1171 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">57</td>
###xml 1185 1187 1171 1173 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">87</td>
###xml 1187 1190 1173 1176 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">124</td>
###xml 1190 1193 1176 1179 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">233</td>
###xml 1193 1195 1179 1181 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">35</td>
###xml 1195 1197 1181 1183 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 1197 1199 1183 1185 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">71</td>
###xml 1199 1201 1185 1187 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">33</td>
###xml 1201 1204 1187 1190 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">194</td>
###xml 1204 1206 1190 1192 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">15</td>
###xml 1175 1206 1161 1192 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">Novel</td><td char="." align="char">208</td><td char="." align="char">57</td><td char="." align="char">87</td><td char="." align="char">124</td><td char="." align="char">233</td><td char="." align="char">35</td><td char="." align="char">15</td><td char="." align="char">71</td><td char="." align="char">33</td><td char="." align="char">194</td><td char="." align="char">15</td></tr>
###xml 1206 1209 1192 1195 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">All</td>
###xml 1209 1212 1195 1198 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">444</td>
###xml 1212 1215 1198 1201 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">144</td>
###xml 1215 1216 1201 1202 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1216 1219 1202 1205 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">357</td>
###xml 1219 1220 1205 1206 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1220 1223 1206 1209 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 1223 1225 1209 1211 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">86</td>
###xml 1225 1226 1211 1212 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1226 1229 1212 1215 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">227</td>
###xml 1229 1230 1215 1216 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0</td>
###xml 1230 1233 1216 1219 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">100</td>
###xml 1206 1233 1192 1219 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">All</td><td char="." align="char">444</td><td char="." align="char">144</td><td char="." align="char">0</td><td char="." align="char">357</td><td char="." align="char">0</td><td char="." align="char">100</td><td char="." align="char">86</td><td char="." align="char">0</td><td char="." align="char">227</td><td char="." align="char">0</td><td char="." align="char">100</td></tr>
###xml 1079 1233 1065 1219 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">dbSNP</td><td char="." align="char">236</td><td char="." align="char">96</td><td char="." align="char">48</td><td char="." align="char">233</td><td char="." align="char">124</td><td char="." align="char">65</td><td char="." align="char">76</td><td char="." align="char">10</td><td char="." align="char">194</td><td char="." align="char">33</td><td char="." align="char">85</td></tr><tr><td align="left">HapMap<sup>b</sup></td><td char="." align="char">80</td><td char="." align="char">42</td><td char="." align="char">102</td><td char="." align="char">79</td><td char="." align="char">278</td><td char="." align="char">22</td><td char="." align="char">33</td><td char="." align="char">53</td><td char="." align="char">67</td><td char="." align="char">160</td><td char="." align="char">30</td></tr><tr><td align="left">Illumina<sup>c</sup></td><td char="." align="char">27</td><td char="." align="char">21</td><td char="." align="char">123</td><td char="." align="char">27</td><td char="." align="char">330</td><td char="." align="char">8</td><td char="." align="char">19</td><td char="." align="char">67</td><td char="." align="char">25</td><td char="." align="char">202</td><td char="." align="char">11</td></tr><tr><td align="left">Novel</td><td char="." align="char">208</td><td char="." align="char">57</td><td char="." align="char">87</td><td char="." align="char">124</td><td char="." align="char">233</td><td char="." align="char">35</td><td char="." align="char">15</td><td char="." align="char">71</td><td char="." align="char">33</td><td char="." align="char">194</td><td char="." align="char">15</td></tr><tr><td align="left">All</td><td char="." align="char">444</td><td char="." align="char">144</td><td char="." align="char">0</td><td char="." align="char">357</td><td char="." align="char">0</td><td char="." align="char">100</td><td char="." align="char">86</td><td char="." align="char">0</td><td char="." align="char">227</td><td char="." align="char">0</td><td char="." align="char">100</td></tr></tbody>
###xml 913 1233 907 1219 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Category</th><th align="left" rowspan="3"><italic>n</italic><sup>a</sup></th><th align="left" colspan="5">MAF&#160;&#8805;1% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th><th align="left" colspan="5">MAF&#160;&#8805;5% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th></tr><tr><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">dbSNP</td><td char="." align="char">236</td><td char="." align="char">96</td><td char="." align="char">48</td><td char="." align="char">233</td><td char="." align="char">124</td><td char="." align="char">65</td><td char="." align="char">76</td><td char="." align="char">10</td><td char="." align="char">194</td><td char="." align="char">33</td><td char="." align="char">85</td></tr><tr><td align="left">HapMap<sup>b</sup></td><td char="." align="char">80</td><td char="." align="char">42</td><td char="." align="char">102</td><td char="." align="char">79</td><td char="." align="char">278</td><td char="." align="char">22</td><td char="." align="char">33</td><td char="." align="char">53</td><td char="." align="char">67</td><td char="." align="char">160</td><td char="." align="char">30</td></tr><tr><td align="left">Illumina<sup>c</sup></td><td char="." align="char">27</td><td char="." align="char">21</td><td char="." align="char">123</td><td char="." align="char">27</td><td char="." align="char">330</td><td char="." align="char">8</td><td char="." align="char">19</td><td char="." align="char">67</td><td char="." align="char">25</td><td char="." align="char">202</td><td char="." align="char">11</td></tr><tr><td align="left">Novel</td><td char="." align="char">208</td><td char="." align="char">57</td><td char="." align="char">87</td><td char="." align="char">124</td><td char="." align="char">233</td><td char="." align="char">35</td><td char="." align="char">15</td><td char="." align="char">71</td><td char="." align="char">33</td><td char="." align="char">194</td><td char="." align="char">15</td></tr><tr><td align="left">All</td><td char="." align="char">444</td><td char="." align="char">144</td><td char="." align="char">0</td><td char="." align="char">357</td><td char="." align="char">0</td><td char="." align="char">100</td><td char="." align="char">86</td><td char="." align="char">0</td><td char="." align="char">227</td><td char="." align="char">0</td><td char="." align="char">100</td></tr></tbody></table>
###xml 1233 1237 1219 1223 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 1271 1274 1257 1260 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAF</italic>
###xml 1233 1415 1219 1401 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="47"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>MAF</italic> minor allele frequency. Only markers with completion rates &gt;50% were used for tagging. Note that HapMap and Illumina SNPs are part of dbSNPs</p>
###xml 1415 1416 1401 1402 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
###xml 1415 1458 1401 1444 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="48"><sup>a</sup>Number of SNPs and indels used for tagging</p>
###xml 1458 1459 1444 1445 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
###xml 1458 1485 1444 1471 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="49"><sup>b</sup>HapMap phase I, II and III</p>
###xml 1485 1486 1471 1472 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
###xml 1485 1512 1471 1498 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="50"><sup>c</sup>Illumina HumanHap610 assay</p>
###xml 1233 1512 1219 1498 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="47"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>MAF</italic> minor allele frequency. Only markers with completion rates &gt;50% were used for tagging. Note that HapMap and Illumina SNPs are part of dbSNPs</p><p textid="48"><sup>a</sup>Number of SNPs and indels used for tagging</p><p textid="49"><sup>b</sup>HapMap phase I, II and III</p><p textid="50"><sup>c</sup>Illumina HumanHap610 assay</p></table-wrap-foot>
###xml 836 1512 830 1498 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab2"><label>Table&#160;2</label><caption><p textid="46">Tag SNP information, bins and coverage in samples of European ancestry</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left" rowspan="3">Category</th><th align="left" rowspan="3"><italic>n</italic><sup>a</sup></th><th align="left" colspan="5">MAF&#160;&#8805;1% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th><th align="left" colspan="5">MAF&#160;&#8805;5% and <italic>r</italic><sup>2</sup>&#160;&#8805;&#160;0.8</th></tr><tr><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th><th align="left" colspan="2">Bins monitored</th><th align="left" colspan="2">Variants monitored</th><th align="left" rowspan="2">Coverage (%)</th></tr><tr><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th><th align="left">Yes</th><th align="left">No</th></tr></thead><tbody><tr><td align="left">dbSNP</td><td char="." align="char">236</td><td char="." align="char">96</td><td char="." align="char">48</td><td char="." align="char">233</td><td char="." align="char">124</td><td char="." align="char">65</td><td char="." align="char">76</td><td char="." align="char">10</td><td char="." align="char">194</td><td char="." align="char">33</td><td char="." align="char">85</td></tr><tr><td align="left">HapMap<sup>b</sup></td><td char="." align="char">80</td><td char="." align="char">42</td><td char="." align="char">102</td><td char="." align="char">79</td><td char="." align="char">278</td><td char="." align="char">22</td><td char="." align="char">33</td><td char="." align="char">53</td><td char="." align="char">67</td><td char="." align="char">160</td><td char="." align="char">30</td></tr><tr><td align="left">Illumina<sup>c</sup></td><td char="." align="char">27</td><td char="." align="char">21</td><td char="." align="char">123</td><td char="." align="char">27</td><td char="." align="char">330</td><td char="." align="char">8</td><td char="." align="char">19</td><td char="." align="char">67</td><td char="." align="char">25</td><td char="." align="char">202</td><td char="." align="char">11</td></tr><tr><td align="left">Novel</td><td char="." align="char">208</td><td char="." align="char">57</td><td char="." align="char">87</td><td char="." align="char">124</td><td char="." align="char">233</td><td char="." align="char">35</td><td char="." align="char">15</td><td char="." align="char">71</td><td char="." align="char">33</td><td char="." align="char">194</td><td char="." align="char">15</td></tr><tr><td align="left">All</td><td char="." align="char">444</td><td char="." align="char">144</td><td char="." align="char">0</td><td char="." align="char">357</td><td char="." align="char">0</td><td char="." align="char">100</td><td char="." align="char">86</td><td char="." align="char">0</td><td char="." align="char">227</td><td char="." align="char">0</td><td char="." align="char">100</td></tr></tbody></table><table-wrap-foot><p textid="47"><italic>SNPs</italic> single nucleotide polymorphisms, <italic>MAF</italic> minor allele frequency. Only markers with completion rates &gt;50% were used for tagging. Note that HapMap and Illumina SNPs are part of dbSNPs</p><p textid="48"><sup>a</sup>Number of SNPs and indels used for tagging</p><p textid="49"><sup>b</sup>HapMap phase I, II and III</p><p textid="50"><sup>c</sup>Illumina HumanHap610 assay</p></table-wrap-foot></table-wrap>
###xml 1512 1519 1498 1505 <label xmlns:xlink="http://www.w3.org/1999/xlink">Table&#160;3</label>
###xml 1529 1530 1515 1516 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1530 1531 1516 1517 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1519 1552 1505 1538 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="51">SNPs with <italic>r</italic><sup>2</sup>&#160;&gt;&#160;0.8 with rs2735839</p>
###xml 1519 1552 1505 1538 <caption xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="51">SNPs with <italic>r</italic><sup>2</sup>&#160;&gt;&#160;0.8 with rs2735839</p></caption>
###xml 1552 1557 1538 1543 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Locus</th>
###xml 1557 1558 1543 1544 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1558 1559 1544 1545 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1557 1559 1543 1545 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left"><italic>r</italic><sup>2</sup></th>
###xml 1559 1562 1545 1548 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">MAF</th>
###xml 1562 1574 1548 1560 <th xmlns:xlink="http://www.w3.org/1999/xlink" align="left">Allele count</th>
###xml 1552 1574 1538 1560 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><th align="left">Locus</th><th align="left"><italic>r</italic><sup>2</sup></th><th align="left">MAF</th><th align="left">Allele count</th></tr>
###xml 1552 1574 1538 1560 <thead xmlns:xlink="http://www.w3.org/1999/xlink"><tr><th align="left">Locus</th><th align="left"><italic>r</italic><sup>2</sup></th><th align="left">MAF</th><th align="left">Allele count</th></tr></thead>
###xml 1574 1583 1560 1569 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs2569735</td>
###xml 1583 1587 1569 1573 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">1.00</td>
###xml 1587 1592 1573 1578 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.156</td>
###xml 1592 1598 1578 1584 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">130|24</td>
###xml 1574 1598 1560 1584 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs2569735</td><td char="." align="char">1.00</td><td char="." align="char">0.156</td><td char="." align="char">130|24</td></tr>
###xml 1598 1607 1584 1593 <td xmlns:xlink="http://www.w3.org/1999/xlink" align="left">rs1058205</td>
###xml 1607 1611 1593 1597 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.91</td>
###xml 1611 1616 1597 1602 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">0.173</td>
###xml 1616 1622 1602 1608 <td xmlns:xlink="http://www.w3.org/1999/xlink" char="." align="char">129|27</td>
###xml 1598 1622 1584 1608 <tr xmlns:xlink="http://www.w3.org/1999/xlink"><td align="left">rs1058205</td><td char="." align="char">0.91</td><td char="." align="char">0.173</td><td char="." align="char">129|27</td></tr>
###xml 1574 1622 1560 1608 <tbody xmlns:xlink="http://www.w3.org/1999/xlink"><tr><td align="left">rs2569735</td><td char="." align="char">1.00</td><td char="." align="char">0.156</td><td char="." align="char">130|24</td></tr><tr><td align="left">rs1058205</td><td char="." align="char">0.91</td><td char="." align="char">0.173</td><td char="." align="char">129|27</td></tr></tbody>
###xml 1552 1622 1538 1608 <table xmlns:xlink="http://www.w3.org/1999/xlink" frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left"><italic>r</italic><sup>2</sup></th><th align="left">MAF</th><th align="left">Allele count</th></tr></thead><tbody><tr><td align="left">rs2569735</td><td char="." align="char">1.00</td><td char="." align="char">0.156</td><td char="." align="char">130|24</td></tr><tr><td align="left">rs1058205</td><td char="." align="char">0.91</td><td char="." align="char">0.173</td><td char="." align="char">129|27</td></tr></tbody></table>
###xml 1622 1626 1608 1612 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 1659 1663 1645 1649 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> MAF</italic>
###xml 1687 1700 1673 1686 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Allele count</italic>
###xml 1622 1726 1608 1712 <p xmlns:xlink="http://www.w3.org/1999/xlink" textid="52"><italic>SNPs</italic> single nucleotide polymorphisms,<italic> MAF</italic> minor allele frequency,<italic> Allele count</italic> major allele|minor allele</p>
###xml 1622 1726 1608 1712 <table-wrap-foot xmlns:xlink="http://www.w3.org/1999/xlink"><p textid="52"><italic>SNPs</italic> single nucleotide polymorphisms,<italic> MAF</italic> minor allele frequency,<italic> Allele count</italic> major allele|minor allele</p></table-wrap-foot>
###xml 1512 1726 1498 1712 <table-wrap xmlns:xlink="http://www.w3.org/1999/xlink" id="Tab3"><label>Table&#160;3</label><caption><p textid="51">SNPs with <italic>r</italic><sup>2</sup>&#160;&gt;&#160;0.8 with rs2735839</p></caption><table frame="hsides" rules="groups"><thead><tr><th align="left">Locus</th><th align="left"><italic>r</italic><sup>2</sup></th><th align="left">MAF</th><th align="left">Allele count</th></tr></thead><tbody><tr><td align="left">rs2569735</td><td char="." align="char">1.00</td><td char="." align="char">0.156</td><td char="." align="char">130|24</td></tr><tr><td align="left">rs1058205</td><td char="." align="char">0.91</td><td char="." align="char">0.173</td><td char="." align="char">129|27</td></tr></tbody></table><table-wrap-foot><p textid="52"><italic>SNPs</italic> single nucleotide polymorphisms,<italic> MAF</italic> minor allele frequency,<italic> Allele count</italic> major allele|minor allele</p></table-wrap-foot></table-wrap>
The main SNP associated with prostate cancer from Eeles et al. (2008b) and with PSA levels from Ahn et al. (2008), rs2735839, is located at 56,056 kb in an approximately 37 kb region of relatively low LD. Tagging the whole region with an r2 threshold of 0.8 and using rs2735839 as an obligate included marker yielded a total of 144 tag SNPs that are necessary to cover the 357 loci with a MAF >1% (Table 2). The bin containing rs2735839 contains two additional SNPs located 0.4 kb (rs2569735, MAF 15.6%) and 1.2 kb centromeric (rs1058205, MAF 17.3%) on chromosome 19. At a MAF of 5% or higher, 86 tags are needed to cover 227 loci (Table 2). Supplemental Table 6 lists the bin and tag SNP information using thresholds of MAF >/=1% or 5% and r2 >/= 0.8. SNPs exhibiting high pairwise LD (r2 >/= 0.8) with rs2735839 are listed in Table 3.Table 2Tag SNP information, bins and coverage in samples of European ancestryCategorynaMAF >/=1% and r2 >/= 0.8MAF >/=5% and r2 >/= 0.8Bins monitoredVariants monitoredCoverage (%)Bins monitoredVariants monitoredCoverage (%)YesNoYesNoYesNoYesNodbSNP23696482331246576101943385HapMapb8042102792782233536716030Illuminac272112327330819672520211Novel20857871242333515713319415All444144035701008602270100SNPs single nucleotide polymorphisms, MAF minor allele frequency. Only markers with completion rates >50% were used for tagging. Note that HapMap and Illumina SNPs are part of dbSNPsaNumber of SNPs and indels used for taggingbHapMap phase I, II and IIIcIllumina HumanHap610 assayTable 3SNPs with r2 > 0.8 with rs2735839Locusr2MAFAllele countrs25697351.000.156130|24rs10582050.910.173129|27SNPs single nucleotide polymorphisms, MAF minor allele frequency, Allele count major allele|minor allele
###end p 45
###begin p 46
Tag SNP information, bins and coverage in samples of European ancestry
###end p 46
###begin p 47
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 38 41 38 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink">MAF</italic>
SNPs single nucleotide polymorphisms, MAF minor allele frequency. Only markers with completion rates >50% were used for tagging. Note that HapMap and Illumina SNPs are part of dbSNPs
###end p 47
###begin p 48
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">a</sup>
aNumber of SNPs and indels used for tagging
###end p 48
###begin p 49
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">b</sup>
bHapMap phase I, II and III
###end p 49
###begin p 50
###xml 0 1 0 1 <sup xmlns:xlink="http://www.w3.org/1999/xlink">c</sup>
cIllumina HumanHap610 assay
###end p 50
###begin p 51
###xml 10 11 10 11 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 11 12 11 12 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
SNPs with r2 > 0.8 with rs2735839
###end p 51
###begin p 52
###xml 0 4 0 4 <italic xmlns:xlink="http://www.w3.org/1999/xlink">SNPs</italic>
###xml 37 41 37 41 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> MAF</italic>
###xml 65 78 65 78 <italic xmlns:xlink="http://www.w3.org/1999/xlink"> Allele count</italic>
SNPs single nucleotide polymorphisms, MAF minor allele frequency, Allele count major allele|minor allele
###end p 52
###begin title 53
In silico genomic and copy number analysis
###end title 53
###begin p 54
###xml 440 444 440 444 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR28">2009</xref>
###xml 624 628 624 628 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR17">2007</xref>
###xml 41 49 <span type="species:ncbi:9606">Children</span>
The Copy Number Variation project at the Children's Hospital of Philadelphia () reports heterozygous deletions within the region sequenced. Deletions were reported in 20/1,320 (1.52%) individuals of European American ancestry and 4/694 (0.58%) individuals of African American ancestry. The CNVs map to 56,022,744-56,024,482 (1,739 bps) and 56,022,744-56,028,151 (5,408 bps) and are seen in 22 and 2 individuals, respectively (Shaikh et al. 2009). The Database of Genomic Variants () reports a loss of small genomic region about 10 kb telomeric (chr19:56,034,084-56,034,206 bps) but it is seen in one individual (Levy et al. 2007).
###end p 54
###begin p 55
###xml 164 168 164 168 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR16">2005</xref>
###xml 251 256 251 256 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 398 402 398 402 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR7">2003</xref>
Substantial mammalian conservation was noted for the exons of all three genes using the UCSC browser (). Sequences with predicted regulatory potential (King et al. 2005) were seen upstream of all genes, and in some intronic regions, especially in the KLK15 gene. No experimentally validated or predicted enhancers are listed in the VISTA browser () for the region (data not shown) (Couronne et al. 2003).
###end p 55
###begin title 56
Discussion
###end title 56
###begin p 57
###xml 249 253 249 253 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR24">2008</xref>
###xml 968 972 968 972 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 1183 1184 1183 1184 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1184 1185 1184 1185 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
###xml 1284 1285 1284 1285 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 1285 1286 1285 1286 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
In this study, we have characterized common genetic polymorphisms (SNPs and indels) spanning a 56 kb region on chromosome 19q13.33 in 78 individuals (156 chromosomes) of European ancestry by using 454 next-generation sequencing (Rothberg and Leamon 2008) coupled with a novel solution-based sequence capture method. This capture method provides a reliable and less labor intensive alternative to long-range PCR when sequencing large genomic regions. We discovered 298 new polymorphisms (116 SNPs and 182 indels) and confirmed 257 previously known loci in the process and constructed a detailed LD map of the region. A large fraction (~65%) of the SNPs described here has also been observed in an early release of the 1000 Genomes Project. Many of the indel polymorphisms detected are rare and validation is required to conclusively establish allele frequencies. Our analysis provides a comprehensive inventory of common genetic variation in the region surrounding the KLK3 gene and allows for the selection of tag SNPs to be used in follow-up studies to thoroughly examine the association of genetic polymorphisms on chromosome 19q13.33 to prostate cancer risk and PSA levels. At an r2 threshold of 0.8 and MAF of 1% or higher, 144 variants are necessary to tag the region, and at an r2 threshold of 0.8 and MAF >5%, 86 loci are required. The resulting improvement in coverage is an additional 78% as compared to HapMap SNPs and 35% over variants known prior to this study (dbSNP).
###end p 57
###begin p 58
###xml 207 212 207 212 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 214 218 214 218 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 223 227 223 227 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 233 237 233 237 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 397 401 397 401 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR18">1985</xref>
###xml 871 875 871 875 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR3">2009</xref>
###xml 969 973 969 973 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR26">2009</xref>
###xml 386 389 <span type="species:ncbi:9606">men</span>
###xml 439 442 <span type="species:ncbi:9606">men</span>
Chromosome 19q13.33 harbors a cluster of 15 kallikrein genes tandemly arranged over ~300 kb. Three genes that belong to this family of serine proteases are located within the region sequenced in this study: KLK15, KLK3 and KLK2. The KLK3 gene encodes PSA, a protein that is produced almost solely by the prostate gland. Small amounts of PSA are detectable in the bloodstream of healthy men (Lilja 1985). An increase in serum PSA levels in men with prostate cancer forms the basis of the PSA test, a widely used screening tool for prostate cancer. The lack of specificity and sensitivity of the test has led to questions about its usefulness as a screening tool for prostate cancer and two large prospective randomized trials are currently underway to directly assess its benefits: The Prostate, Lung, Colorectal and Ovarian Cancer Screening trial (PLCO) (Andriole et al. 2009) and the European Randomized Study of Screening for Prostate Cancer (ERSPC) (Schroder et al. 2009).
###end p 58
###begin p 59
###xml 4 8 4 8 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 13 18 13 18 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 84 88 84 88 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 401 405 401 405 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR19">2007</xref>
###xml 423 427 423 427 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 432 436 432 436 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK2</italic>
###xml 590 594 590 594 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2000</xref>
###xml 657 661 657 661 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR12">2000</xref>
###xml 664 669 664 669 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 702 706 702 706 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 851 856 851 856 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK15</italic>
###xml 1001 1005 1001 1005 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR29">2003</xref>
###xml 1021 1025 1021 1025 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR35">2001</xref>
###xml 204 209 <span type="species:ncbi:9606">human</span>
The KLK2 and KLK15 genes have also been implicated in prostate cancer etiology. The KLK2 gene is expressed in the prostate gland and has been proposed as a potential marker for prostate cancer. Like PSA, human kallikrein 2 (hK2) levels in the bloodstream are strongly associated with prostate cancer but do not increase the value of total PSA measurements for predicting risk of disease (Lilja et al. 2007). Interestingly, KLK3 and KLK2 share ~80% nucleotide sequence identity across exons, introns and non-coding regions of the two genes, suggesting a recent duplication event (Gan et al. 2000). PSA and hK2 also share ~80% amino acid identity (Gan et al. 2000). KLK15 is the next gene centromeric to KLK3 and shares considerable similarities to other kallikrein genes. It encodes yet another member of the kallikrein family, hK15. Expression of the KLK15 gene appears to be upregulated in a large percentage of prostate cancers and is possibly associated with a higher stage disease (Stephan et al. 2003; Yousef et al. 2001).
###end p 59
###begin p 60
###xml 102 106 102 106 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 197 201 197 201 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR8">2003</xref>
###xml 203 207 203 207 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR9">2008</xref>
###xml 220 224 220 224 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR21">2007</xref>
###xml 476 481 476 481 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR11">2008b</xref>
###xml 510 514 510 514 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR1">2008</xref>
###xml 605 606 605 606 <italic xmlns:xlink="http://www.w3.org/1999/xlink">r</italic>
###xml 606 607 606 607 <sup xmlns:xlink="http://www.w3.org/1999/xlink">2</sup>
Previous association studies with candidate or tag SNPs have reported a number of SNPs in or near the KLK3 gene that appear to be associated with prostate cancer, PSA levels or both (Cramer et al. 2003; 2008; Pal et al. 2007). Results from GWAS and their follow-up studies are conflicting, and it appears that the association to prostate cancer may depend on how control individuals were selected. The SNP most significantly associated with prostate cancer risk (Eeles et al. 2008b) and PSA levels (Ahn et al. 2008), rs2735839, lies in a region of relatively low LD. We discovered two markers in high LD (r2 >/= 0.8) with rs2735839; thus, these variants are the most likely to be advanced in laboratory analyses designed to investigate the biological basis of the association signal(s).
###end p 60
###begin p 61
###xml 96 100 96 100 <xref xmlns:xlink="http://www.w3.org/1999/xlink" ref-type="bibr" rid="CR14">2008</xref>
###xml 654 658 654 658 <italic xmlns:xlink="http://www.w3.org/1999/xlink">KLK3</italic>
###xml 182 190 <span type="species:ncbi:9606">patients</span>
Prostate cancer is the second leading cause of cancer deaths in the United States (Jemal et al. 2008). It shows both indolent and aggressive forms and it is difficult to distinguish patients that require aggressive therapy and management from those that should be left to watchful waiting. Although the benefits of PSA screening in detecting earlier stage cancers may be important, this leads to a significant intervention and unnecessary treatment. Evidence for or against the efficacy of PSA screening in reducing morbidity and mortality due to prostate cancer is eagerly awaited. Our effort to comprehensively describe common genetic variation in the KLK3 locus on chromosome 19q13.33 should enable a rational approach towards the follow-up analyses of the role genetic variation plays on PSA levels and prostate cancer risk.
###end p 61
###begin title 62
Electronic supplementary material
###end title 62
###begin p 63
Below is the link to the electronic supplementary material.
###end p 63
###begin p 64
Supplementary material (PDF 9 kb)
###end p 64
###begin p 65
Supplementary Figure 1 (EPS 1626 kb)
###end p 65
###begin p 66
Supplementary Figure 2 (EPS 1601 kb)
###end p 66
###begin p 67
Supplementary Figure 3 (JPG 1601 kb)
###end p 67
###begin p 68
Supplementary Tables (PDF 27 kb)
###end p 68
###begin p 69
Supplementary Table 2 (XLS 183 kb)
###end p 69
###begin p 70
Supplementary Table 6 (XLS 69 kb)
###end p 70
###begin p 71
###xml 288 293 <span type="species:ncbi:9606">Human</span>
This project has been funded in whole or in part with federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. HHSN261200800001E. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the US Government.
###end p 71
###begin p 72
###xml 0 30 0 30 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Conflict of interest statement</bold>
Conflict of interest statement All authors report no financial interests or potential conflicts of interests.
###end p 72
###begin p 73
###xml 0 11 0 11 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Open Access</bold>
Open Access This article is distributed under the terms of the Creative Commons Attribution Noncommercial License which permits any noncommercial use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.
###end p 73
###begin title 74
References
###end title 74
###begin article-title 75
Variation in KLK genes, prostate-specific antigen and risk of prostate cancer
###end article-title 75
###begin article-title 76
###xml 20 25 <span type="species:ncbi:9606">human</span>
Direct selection of human genomic loci by microarray hybridization
###end article-title 76
###begin article-title 77
Mortality results from a randomized prostate-cancer screening trial
###end article-title 77
###begin article-title 78
Haploview: analysis and visualization of LD and haplotype maps
###end article-title 78
###begin article-title 79
Two androgen response regions cooperate in steroid hormone regulated activity of the prostate-specific antigen promoter
###end article-title 79
###begin article-title 80
An androgen response element in a far upstream enhancer region is essential for high, androgen-regulated activity of the prostate-specific antigen promoter
###end article-title 80
###begin article-title 81
Strategies and tools for whole-genome alignments
###end article-title 81
###begin article-title 82
Association between genetic polymorphisms in the prostate-specific antigen gene promoter and serum prostate-specific antigen levels
###end article-title 82
###begin article-title 83
Association of prostate-specific antigen promoter genotype with clinical and histopathologic features of prostate cancer
###end article-title 83
###begin article-title 84
Reply to "Variation in KLK genes, prostate-specific antigen and risk of prostate cancer"
###end article-title 84
###begin article-title 85
Multiple newly identified loci associated with prostate cancer susceptibility
###end article-title 85
###begin article-title 86
Sequencing and expression analysis of the serine protease gene cluster located in chromosome 19q13 region
###end article-title 86
###begin article-title 87
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status
###end article-title 87
###begin article-title 88
Cancer statistics, 2008
###end article-title 88
###begin article-title 89
###xml 134 142 <span type="species:ncbi:9606">patients</span>
Individual and cumulative effect of prostate cancer risk-associated variants on clinicopathologic variables in 5, 895 prostate cancer patients
###end article-title 89
###begin article-title 90
Evaluation of regulatory potential and conservation scores for detecting cis-regulatory modules in aligned mammalian genome sequences
###end article-title 90
###begin article-title 91
###xml 45 50 <span type="species:ncbi:9606">human</span>
The diploid genome sequence of an individual human
###end article-title 91
###begin article-title 92
A kallikrein-like serine protease in prostatic fluid cleaves the predominant seminal vesicle protein
###end article-title 92
###begin article-title 93
Long-term prediction of prostate cancer up to 25 years before diagnosis of prostate cancer using prostate kallikreins measured at age 44 to 50 years
###end article-title 93
###begin article-title 94
Interval estimation for the difference between independent proportions: comparison of eleven methods
###end article-title 94
###begin article-title 95
###xml 101 104 <span type="species:ncbi:9606">men</span>
Tagging SNPs in the kallikrein genes 3 and 2 on 19q13 and their associations with prostate cancer in men of European origin
###end article-title 95
###begin article-title 96
Effect of verification bias on screening for prostate cancer by measurement of prostate-specific antigen
###end article-title 96
###begin article-title 97
Impact of age, benign prostatic hyperplasia, and cancer on prostate-specific antigen level
###end article-title 97
###begin article-title 98
The development and impact of 454 sequencing
###end article-title 98
###begin article-title 99
Primer3 on the WWW for general users and for biologist programmers
###end article-title 99
###begin article-title 100
Screening and prostate-cancer mortality in a randomized European study
###end article-title 100
###begin article-title 101
Prostate-specific antigen expression is regulated by an upstream enhancer
###end article-title 101
###begin article-title 102
Quantitative analysis of kallikrein 15 gene expression in prostate tissue
###end article-title 102
###begin article-title 103
Statistical significance for genomewide studies
###end article-title 103
###begin article-title 104
Multiple loci identified in a genome-wide association study of prostate cancer
###end article-title 104
###begin article-title 105
###xml 36 39 <span type="species:ncbi:9606">men</span>
Prevalence of prostate cancer among men with a prostate-specific antigen level < or = 4.0 ng per milliliter
###end article-title 105
###begin article-title 106
Association of prostate cancer risk variants with clinicopathologic characteristics of the disease
###end article-title 106
###begin article-title 107
Genome-wide association study of prostate cancer identifies a second risk locus at 8q24
###end article-title 107
###begin article-title 108
###xml 25 30 <span type="species:ncbi:9606">human</span>
Molecular cloning of the human kallikrein 15 gene (KLK15). Up-regulation in prostate cancer
###end article-title 108
###begin p 109
###xml 0 33 0 33 <bold xmlns:xlink="http://www.w3.org/1999/xlink">Electronic supplementary material</bold>
Electronic supplementary material
###end p 109
###begin p 110
The online version of this article (doi:10.1007/s00439-009-0751-5) contains supplementary material, which is available to authorized users.
###end p 110

